[1]
|
J. L. Witzum, “Drug Used in the Treatment of Hyperlipopro-teinemias,” 9th Edition, Mc Graw Hill, New york, 1996.
|
[2]
|
L. Posvar, L. L. Radulovic, D. D. Cilla, et al., “To-larance and Pharmacokinetics of Signal-Dose Atrovastatin, a Potent Inhibitor of HMG-CoA Reductase, in Health Subjects,” The Journal of Clinical Pharmacology, Vol. 36, No. 8, 1996, pp. 728-731.
|
[3]
|
S. Budavari, “The Merck Index, an Ency-clopaedia of Chemicals, Drugs and Biologicals,”13th Edition, Merck, White House Station, 2001.
|
[4]
|
T. G. Altuntas and N. Erk, “Liquid Chromatographic Determination of Atorvastatin in Bulk Drug, Tablets, and Human Plasma,” Journal of Liquid Chromatography & Related Technologies, Vol. 27, No. 1, 2004, pp. 83-93.
doi:10.1081/JLC-120027087
|
[5]
|
M. K. Pasha, S. Muzeeb, S. J. S. Basha, D. Shashikumar, R. Mullangi and N. R. Srinivas, “Analysis of Five HMG- CoA Reductase Inhibi-tors—Atorvastatin, Lovastatin, Pra-vastatin, Rosuvastatin and Simvastatin: Pharmacological, Pharmacokinetic and Analytical Overview and Development of a New Method for Use in Pharmaceutical Formulations Analysisand In Vitro Metabolism Studies,” Biomedical Chromatography, Vol. 20, No. 3, 2006, pp. 282-293. doi:10.1002/bmc.561
|
[6]
|
U. Seshachalam and C. B. Kothapally, “HPLC Analysis for Simultaneous Determination of Atorvastatin and Ezetimibe in Pharmaceutical Formulations,” Journal of Liquid Chromatography & Related Technologies, Vol. 31, No. 5, 2008, pp. 714-721.
doi:10.1080/10826070701854402
|
[7]
|
S. Erturk, E. S. Aktas, L. Ersoy and S. Ficicioglu, “An HPLC Method for the Determination of Atorvastatin and Its Impurities in Bulk Drug and Tablets,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 33, No. 5, 2003, pp. 1017-1023.
doi:10.1016/S0731-7085(03)00408-4
|
[8]
|
R. Nirogi, K. Mudigonda and V. Kandikere, “Chromatography-Mass Spectrometry Methods for the Quantification of Statins in Biological Samples,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 44, No. 2, 2007, pp. 379-387. doi:10.1016/j.jpba.2007.02.008
|
[9]
|
L. Novakova, D. Satinsky and P. Solich, “HPLC Methods for the Determination of Sim-vastatin and Atorvastatin,” TrAC Trends in Analytical Chemistry, Vol. 27, No. 4, 2008, pp. 352-367.
|
[10]
|
M. Bakshi and S. Singh, “Development of Validated Stability-Indicating Assay Methods—Critical Review,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 28, No. 6, 2002, pp. 1011-40.
doi:10.1016/S0731-7085(02)00047-X
|
[11]
|
CPMP/ICH/281/95, “Note for Guidance on Validation of Analytical Procedure: Methodology, ICH Topic Q2B Validation of Analytical Procedure: Methodology, Step 4,” 1996. www.ich.org.
|
[12]
|
CPMP/ICH/381/95, “Note for Guidance on Validation of Analytical Method: Definition and Terminology, Step 5,” 1994. www.ich.org.
|